The safety and tolerability of atypical antipsychotics in bipolar disorder.
Atypical antipsychotics (aAPs), have become a first-line treatment option, both in schizophrenia and bipolar disorders. Almost all aAPs now have proven efficacy in acute mania, some also in bipolar depression and in maintenance treatment. This provides reliable data on their safety and tolerability in this particular group of patients. This review focuses on the safety and tolerability of aAPs in the treatment of bipolar disorders. Both tolerability, for example, extrapyramidal symptoms, and safety issues, for example, occurrence of weight gain and hyperglycaemia, will be highlighted for olanzapine, quetiapine, risperidone, ziprasidone and aripiprazole.
Seemüller
Florian
F
Department of Psychiatry, Ludwigs-Maximilians-University, Nussbaumstr. 7, 80336 Munich, Germany.
Forsthoff
Anna
A
Dittmann
Sandra
S
Born
Christoph
C
Bernhard
Britta
B
Severus
W Emanuel
WE
Grunze
Heinz
H
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001714:Bipolar Disorder / Q000188:drug therapy*; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D015430:Weight Gain
D014150:Antipsychotic Agents